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We report the results of whole-genome and tran-
scriptome sequencing of tumor and adjacent normal
tissue samples from 17 patients with non-small cell
lung carcinoma (NSCLC). We identified 3,726 point
mutations and more than 90 indels in the coding
sequence, with an average mutation frequency
more than 10-fold higher in smokers than in never-
smokers. Novel alterations in genes involved in
chromatin modification and DNA repair pathways
were identified, along with DACH1, CFTR, RELN,
ABCB5, and HGF. Deep digital sequencing revealed
diverse clonality patterns in both never-smokers and
smokers. All validated EFGR and KRAS mutations
were present in the founder clones, suggesting
possible roles in cancer initiation. Analysis revealed
14 fusions, including ROS1 and ALK, as well as novel
metabolic enzymes. Cell-cycle and JAK-STAT path-
ways are significantly altered in lung cancer, along
with perturbations in 54 genes that are potentially
targetable with currently available drugs.
INTRODUCTION
Lung cancer is a leading cause of cancer-related death globally
(Ferlay et al., 2010). Non-small cell lung cancer (NSCLC), the
most common type, comprises three histological subtypes:
adenocarcinoma, squamous cell carcinoma, and large cell carci-
noma. Approximately 10%–40%of patients diagnosed with lungCcancer report no history of tobacco smoking. The proportion of
patients who are lifelong never-smokers is higher in parts of
Asia (Subramanian and Govindan, 2007). Environmental and
occupational exposures (Ng, 1994), as well as genetic suscep-
tibility (Sellers et al., 1990; Yang et al., 1999), are thought to
contribute to lung cancer risk in never-smokers.
Inhibitors of epidermal growth factor receptor (EGFR) tyrosine
kinase (TK), gefitinib and erlotinib, have shown substantial
activity in patients whose tumor cells harbor specific mutations
in the EGFR TK domain (Lynch et al., 2004). The recent
discovery of a fusion kinase involving the EMAP-like protein 4
(EML4) and anaplastic lymphoma kinase (ALK) genes in tumor
specimens from some patients with NSCLC (mostly adenocar-
cinoma) and the dramatic response to crizotinib, as well as
the identification of fusion kinases involving RET and ROS1,
have reinvigorated efforts to identify novel genomic alterations
that could be therapeutic targets (Kohno et al., 2012; Lipson
et al., 2012; Soda et al., 2007; Takeuchi et al., 2012). EGFR
TK domain mutations and fusion kinases involving EML4-ALK
are present more often in the tumor specimens from lifelong
never-smokers than from smokers (Soda et al., 2007; Subrama-
nian and Govindan, 2007).
In our previous studies, SNP-array-based analysis of 371 lung
adenocarcinomas has previously revealed 57 significant copy
number alterations (Weir et al., 2007), including the most
common amplification of TITF1, a lineage-specific transcription
factor responsible for lung development (Kendall et al., 2007). In
addition, sequencing of the coding exons of 623 candidate
cancer genes in 188 lung adenocarcinomas identified 26
significantly mutated genes in lung adenocarcinoma, con-
sisting of a set of oncogenes (EGFR, KRAS, ephrin receptor
genes, ERBB4, KDR, FGFR4, and NTRK genes) and tumorell 150, 1121–1134, September 14, 2012 ª2012 Elsevier Inc. 1121
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Figure 1. Mutation Landscape in Lung Cancer
(A and B) A heatmap of significant genetic events in 17 NSCLC samples is provided for both (A) genes previously implicated lung cancer and (B) novel genes found
to be recurrently altered in the present study. Events, including point mutations, truncation mutations, copy number gains and losses, and larger structural
variations are color coded according to the legend provided.
(C) Clinical characteristics of the 17 NSCLC patients.
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suppressors (TP53, STK11, NF1, RB1, ATM, and APC) (Ding
et al., 2008).
Clearly, discovering novel genetic alterations in lung cancer,
from point mutations to large structural variants, requires
a comprehensive genome-wide approach. We report a
sequencing-based study of tumor specimens from 16 patients
with adenocarcinoma and one patient with large cell carcinoma
of the lung by using whole-genome and transcriptome
sequencing. We identified several novel point mutations and
novel fusions that are potentially targetable for therapy. Deep
digital sequencing of somatic mutations, for the first time,
revealed that lung cancers from both smokers and never-
smokers are often heterogeneous and consist of subclonal
populations. Our findings highlight the importance of com-
prehensive and integrated analysis of the genome and tran-
scriptome of lung cancers for identifying novel pathways and
therapeutic targets.
RESULTS
Study Design and Case Descriptions
Tumor and adjacent normal tissue samples for whole-genome
sequencing were obtained from patients diagnosed with NSCLC
who underwent definitive surgical resection prior to receiving
chemotherapy or radiation at the Alvin J. Siteman Cancer Center
at Washington University School of Medicine. All samples were
subjected to pathology review to establish the histologic diag-
nosis and tumor cellularity. Only samples with tumor nuclei
greater than or equal to 50% of total cellular nuclei in the section
were utilized for this study. We identified 17 patients who met all
of the above criteria, resulting in a cohort comprising 16 tumors
with adenocarcinoma histology and one with large cell carci-
noma histology. The median age of patients was 63 years (range
24–77). Five patients included in the study reported no history of
tobacco smoking (referred to as ‘‘never-smokers’’ hereafter),
and one patient had a very light history of tobacco smoking
(ten packs per year), having quit smoking 38 years before devel-
oping lung cancer (referred to as ‘‘former light smoker’’ hereafter)
(Figure 1). Clinical characteristics including tumor stage, treat-
ment received, and outcome are provided in Table S1 (available
online). Histological images are provided in Data S1. The study
was approved by the Human Research Protection Office
(HRPO) at the Washington University School of Medicine.
The initial data set for this study included whole-genome
sequencing (WGS) paired-end sequencing data generated using
17 lung cancer (LUC) tumor-normal pairs, with haploid coverage
ranging from 25.03- to 64.49-fold (Table S2). Point mutations,
small (<30 bp) indels, copy number alterations, and structural
variants (SVs) were discovered by using various computational
approaches (Chen et al., 2009; Larson et al., 2012; Li et al.,
2009; McKenna et al., 2010; Ye et al., 2009). Point mutations
and indels identified by WGS were classified into four tiers as
described previously (Mardis et al., 2009) (Extended Experi-(D) A stacked bar graph representing the total number of tier 1 mutations in e
synonymous mutations.
(E) A stacked bar graph representing the frequency of each type of base substitu
See also Figure S1, Data S2 and S3, and Tables S1, S2, S3, S4, S5, S6, S8, S9,
Cmental Procedures and Tables S3 and S4). Custom sequence
capture arrays were used to validate putative WGS mutations
(Table S5). Variants of interest identified by WGS were extended
by recurrence screening in an independent set of 94 primary
lung adenocarcinomas (Table S6). RNA sequencing (RNA-seq)
data were generated for all 17 tumors and a single, matched
normal adjacent tissue to LUC9, with 11,578–14,507 genes
detected as expressed in each tumor (Table S7).
Genomic Landscape of Lung Cancer in Relation to
Tobacco Smoking
Substantial differences in the mutational burden, spectrum, and
affected genes were found between smokers and never-
smokers (Figure 1). Of the 12 samples from tobacco smokers
(including the former light smoker), we observed one cancer
genome (LUC9) with a significantly higher number of point muta-
tions (tier 1: 1,363) when compared to the other tumor samples
(Figure 1). This sample meets our criterion for ‘‘hypermutation,’’
which is defined as having a total number of tier 1 mutations at
least 2 SD greater (1 SD = 329) than the rest of the samples.
The total number of point mutations (tiers 1–3) was much higher
in tobacco smokers (median 15,659, range 7,424–26,202, LUC9
not included) relative to never-smokers (median 888, range
842 –1,268). Similarly, the total number of point mutations
involving coding regions (tier 1) also wasmuch higher in smokers
(median 209, range 104–1363) compared to never-smokers
(median 18, range 10–22). The total number of point mutations
in the former light smoker was 403 in tiers 1–3, with only 10 in
tier 1 (Table S8). Consistent with previous reports (Ding et al.,
2008; Lee et al., 2010), lung cancer due to tobacco smoking is
associated with a significantly higher number of mutations per
Mb (mutations per Mb: median 10.5, range 4.9–17.6, LUC9
not included) compared to never-smokers with lung cancer
(mutations per Mb: median 0.6, range 0.6–0.9) and a single
former light smoker with lung cancer (0.3 mutations per Mb) in
our study. Figure 1 illustrates the different characteristics of
mutations in patients according to their smoking status. In
particular, C:G/A:T transversions were noted predominantly
in tobacco smokers, whereas C:G/T:A transitions were the
most frequent type of point mutations in never-smokers with
lung cancer and the former light smoker, which is consistent
with previously reported studies (Ding et al., 2008; Lee et al.,
2010). The mutational spectrum of the single large cell carci-
noma sample was not different from those of lung adenocarci-
noma associated with tobacco smoking. Overall, the number
of point mutations in the lung cancer genome appears to be
closely related to the patient’s tobacco smoking status, and
the landscape of the former light smoker genome suggests
a possible dose-response relationship between the amount
and duration of tobacco smoke exposure and the extent of
mutational burden. The hypermutated tumor (LUC9) was found
to have point mutations involving several DNA repair genes,
including PRKDC, TP53, MSH3, POLK, MSH4, FANCM,ach patient, color proportioned by the number of synonymous versus non-
tion for all tier 1 point mutations in 17 NSCLC genomes.
S10, S12, S13, S16, and S17.
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FBXW7, TOP2B,MLH1,RPA2,BUB1, FANCB, and TOP1 (Wood
et al., 2001) (http://www.genesilico.pl/index.php/home.html). It
is possible that these mutations in DNA repair genes resulted
in an impaired ability to repair sustained DNA damage induced
by chronic tobacco smoke.
Somatically Mutated Genes in Lung Cancer
Recurrent Mutations Previously Reported
in Lung Cancer
Given the limited sample size of our study, to prioritize additional
important mutations, we used an alternative analysis focusing
on tier 1mutations previously reported in lung cancer as reported
in the Catalogue of Somatic Mutations in Cancer (COSMIC)
(http://www.sanger.ac.uk/genetics/CGP/cosmic/). In addition
to the well-known mutations involving KRAS, EGFR, and TP53
genes, this approach revealed several other recurrent point
mutations in kinase genes thatmay serve aspotential therapeutic
targets, including BRAF (D594N and V413L), JAK2 (V615L and
M532V), JAK3 (A1090S), EPHA3 (M320I, G187R, T393K, and
R728L), EPHA4 (E670D), STK11 (D327fs), LTK (R669*), MET
(Q99L and Y1003N), and ITK (Y588*) (Figure 1 and Table S3).
Novel Significantly Mutated Genes in Lung Cancer
We previously developed the significantly mutated gene (SMG)
algorithm to detect, in an unbiased manner, biologically signifi-
cant variants from cancer genome sequencing data (Dees
et al., 2012) (Figure 1). The statistical significance of mutations
in each gene is determined by comparing themutation frequency
of each gene with the background mutation rate across all
samples. The algorithm identified nine genes that were highly
significant (Table S9, false discovery rate q% 0.05 for two tests,
see Extended Experimental Procedures). We did not find any
correlations between gender and mutations (Table S10).
Of the nine SGMs, mutations involving DACH1, RELN, and
ABCB5 genes have not been previously reported in lung cancer.
Low DACH1 expression levels were associated with poor
prognosis in patients with breast cancer (Wu et al., 2006).
DACH1 has been reported to have a tumor suppressor role in
prostate cancer and in gliomas (Watanabe et al., 2011; Wu
et al., 2009). In our study, two frameshift mutations (LUC9:
K636fs and LUC13: A656fs) in the coiled-coil domain (CCD) of
the DACH1 gene were identified. Analysis of RNA-seq data for
DACH1 from the hypermutated sample pair revealed an FPKM
(fragments per kilobase of exon per million fragments mapped;
Extended Experimental Procedures) expression level of 2.257
in the normal sample, whereas the tumor sample had an expres-
sion level of 0.962. This result is corroborated in the WGS data,
in which three samples (LUC9, LUC15, and LUC20) show a
DACH1 copy number loss in the tumor sample (Table S11).
Lastly, our recurrent screening (n = 96) for mutations in DACH1
identified two more nonsilent mutations, including one missense
mutation (D584G) and one nonsense mutation (G430*).
Recurrent point mutations in the RELN gene were identified
in three samples (LUC13: A1189D, LUC18: Y3301*; LUC9:
H3224N, I1228N; and R301I). Mutations in the RELN gene
have been identified in pediatric early T cell precursor acute
lymphoblastic leukemia (Zhang et al., 2012). We also discovered
three samples with nonsynonymous point mutations (LUC11:
G347R, LUC12: M521L, and LUC9: P580S and A687S) in the1124 Cell 150, 1121–1134, September 14, 2012 ª2012 Elsevier Inc.ABCB5 gene, which encodes a membrane transporter protein
belonging to the ATP-binding cassette (ABC) protein family.
There were other genes that did not meet the threshold for
significance on the SMG test but were included for testing for
recurrence in our extension set (n = 96). Three candidate genes,
HGF, CFTR, and MICAL3, were chosen for various reasons,
including the possibility of being a therapeutic target for lung
cancer (HGF) and their association with other lung diseases
(CFTR, cystic fibrosis), or they were associated with never-
smokers (MICAL3). The overall prevalence of these mutations
in the combined set of 17 samples used for lung cancer whole-
genome analysis and 96 samples used for validation was 4.4%
(HGF), 4.4% (CFTR), and 0.9% (MICAL3) (Table S12). We identi-
fied five point mutations involving the CFTR gene in four
samples; these included four missense (LUC18: M82V, LUC9:
R170L, F354I, and A309S from panel screening) and one
nonsense (LUC18: S478*) mutations. Two of the five point muta-
tions involving CFTR (M82V and S478*) have been previously
reported in patients with cystic fibrosis (Koukourakis et al.,
2003). Recently, drugs that target specific CFTR point mutations
(G551D and other nonsense mutations) have shown therapeutic
benefit in patients with cystic fibrosis (Ramsey et al., 2011).
Chromatin-associated genes are found to bemutated in tumor
samples from both never-smokers and smokers. We identified
73 nonsynonymous point mutations in 66 chromatin-associated
genes, including mutations involving SETD2, ARID1A, and
ARID2 (Table S13). A nonsense mutation (Q1977*) in SETD2
was identified in LUC11 from a never-smoker, and twomissense
mutations (E1735K in ARID1A and V465L in ARID2) were identi-
fied in two smokers (LUC14 and LUC18). Exome sequencing of
hepatocellular carcinomas has reported recurrent mutations
involving the ARID2 gene (Li et al., 2011), and frequent mutations
in ARID1A have been reported in ovarian clear cell carcinoma
(Jones et al., 2010a) and endometriosis-associated ovarian
cancer (Wiegand et al., 2010). Several point mutations in histone
methyltransferase genes (MLL3, MLL4,WHSC1L1, and ASH1L)
were identified as well.
Tumor Heterogeneity Analysis Using Deep Digital
Sequencing Data
By performing targeted sequencing with high read coverage
(mean depth of 381 reads) to validate variants detected by
WGS, we were able to accurately estimate the variant allele
frequencies (VAFs) for somatic mutations identified in each
tumor sample. Based on the VAF distribution, we were able to
estimate the number and size of the clonal populations in each
tumor sample. Recent studies have shown the importance of
clonal evolution in tumor progression and development of
metastasis (Ding et al., 2012; Gerlinger et al., 2012). Using muta-
tions from copy-number-neutral regions, we found that ten
tumors had a multiclonal signature, and seven tumors were
largely monoclonal (Table 1 and Figure 2). We did not find any
correlation between smoking status and tumor clonality. Based
on the VAFs of mutations, we were able to identify mutations
that were present in the founding clone and/or the subclone(s).
All EFGR and KRAS mutations validated in our cohort were
present in the founder clones of the associated tumor samples
(for example, the EGFR mutation in LUC15 at 19% VAF,
Table 1. Clonality and Purity Summary for 17 Cases
Case Gender Smoking Status
Dominant / Secondary
Clone VAFs
Tumor Purity (Based on
Dominant Clone VAFs)
Tumor Purity (Based on
Chr. X VAFs) Clonality Status
LUC1 male light smoker 12.7% 25.4% 30.7% monoclonal
LUC2 female smoker 22.5% /12.9% 45.0% n/a biclonal
LUC4 male smoker 14.9% 29.8% 29.8% monoclonal
LUC6 female never-smoker 24.7% 49.4% n/a monoclonal
LUC7 female never-smoker 21.3% /10.8% 42.6% n/a biclonal
LUC8 female smoker 22.7% 45.4% n/a monoclonal
LUC9 female smoker 41.1% /20.4% 82.2% n/a biclonal
LUC10 male smoker 43.1% /21.9% 86.2% 71.4% biclonal
LUC11 male never-smoker 28.8% 57.6% 41.0% monoclonal
LUC12 male smoker 10.4% 20.8% 24.3% monoclonal
LUC13 male smoker 41.9% /21.3% 83.8% 58.6% biclonal
LUC14 female smoker 29.5% /16.2% 59.0% n/a biclonal
LUC15 female never-smoker 19.2% /10.8% 38.4% n/a biclonal
LUC16 female never-smoker 47.2% /15.3% 94.4% n/a biclonal
LUC17 female smoker 13.9% /11.2% 27.8% n/a biclonal
LUC18 male smoker 18.8% /9.8% 37.6% 31.5% biclonal
LUC20 female smoker 39.9% 79.8% n/a monoclonalFigure 2D, and the KRAS mutation in LUC10 at 48% VAF, Fig-
ure 2F). The clonal distributions of other mutations involving
genes such as HGF were varied between samples. In the
LUC9 tumor in particular, which exhibits two distinct mutation
clusters at median VAFs 41.1% and 20.4%, an HGF mutation
exists in both subclones (Figure 2E). We extended the subclon-
ality analyses to copy number alterations (in particular, deletions)
for LUC9 by using an algorithm that compares the observed read
counts with the expected diploid read counts in the affected
intervals. We found a biclonal pattern in the deletions that was
similar to what we observed with SNV analysis described above
(Table S14 and Figure S1). In LUC10, an HGF mutation exists in
the secondary clone at 17%VAF (Figure 2F). It is likely that EGFR
and KRAS mutations are initiating events for lung cancer, and
other mutations such as HGF mutations are acquired later and
perhaps are important for tumor maintenance and progression.
Of the ten tumor samples that had biclonal population, eight
had one or more potentially targetable mutations in the subclone
(Table S15). These eight samples also had at least one additional
targetable mutation in the dominant clone. We believe that our
analysis represents an underestimation of tumor heterogeneity
due to the limitation of detecting low-frequency mutations in
the tumor genome with an average of 303 haploid coverage. It
is conceivable that future studies will need to focus on drug ther-
apies affecting critical genes or key pathways not only in the
dominant clone but also in the subclone. A treatment strategy
focused mainly on the dominant clones could potentially fail,
owing to emergence of subclones that are not originally targeted
for therapy.
Structural Variants Identified by Whole-Genome
and Transcriptome Sequencing
Among the validated 173 somatic rearrangements detected by
WGS data were 59 interchromosomal translocations, 7 tandemCduplications, 74 deletions, and 33 inversions (Table S16). The
majority of the interchromosomal events were clustered in
four samples: three from smokers and one from a never-smoker
(Data S2). The never-smoker (LUC7) tumor genome is character-
ized by widespread chromosomal disruption that is consistent
with chromothripsis (Stephens et al., 2011). We identified
15 validated interchromosomal translocation events between
chromosome 5 and other chromosomes across the LUC7
tumor genome, with most events connecting the distal end of
chromosome 5q with various locations on chromosomes 10,
12, 17, and 20. Copy number alterations often co-occur with
translocation breakpoints, which is consistent with previously
described chromothripsis events. We did not identify any TP53
mutations in this tumor, though mutations involving the TP53
gene have been reported to be associated with chromothripsis
(Rausch et al., 2012).
We also analyzed the tumor genomes for novel fusion genes,
an area of great interest therapeutically with the recent discovery
of novel fusions involving kinase genes ALK, ROS, and RET in
NSCLC (Takeuchi et al., 2012). With combined whole-genome
and transcriptome sequencing, we were able to systematically
identify and validate fusion genes. Three different algorithms,
ChimeraScan (Iyer et al., 2011), defuse (McPherson et al.,
2011), and BreakFusion (Chen et al., 2012), were used to identify
fusion genes from the transcriptome sequencing data. High-
confidence fusions were then orthogonally validated by analysis
of the whole-genome DNA sequencing data. Based on this
analysis, we identified 14 high-confidence fusions (Table S17
and Extended Experimental Procedures), including an in-frame
novel fusion KDELR2-ROS1 in LUC11 and an EML4-ALK
fusion in LUC16. Even though ROS1 kinase fusions have been
previously reported in patients diagnosed with NSCLC and
cholangiocarcinoma (Bergethon et al., 2012; Gu et al., 2011;
Rikova et al., 2007), we identified a novel 50 partner (KDELR2)ell 150, 1121–1134, September 14, 2012 ª2012 Elsevier Inc. 1125
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Figure 2. Tumor Clonality Analysis in Lung Cancer
(A) Schematic depiction of a monoclonal tumor sample with a higher tumor purity (i.e., few normal cells).
(B) Schematic depiction of a biclonal tumor sample consisting of a small number of contaminating normal cells, a primary or ‘‘founder’’ clone (pink tumor cells),
and a secondary clone (purple tumor cells). The cells of the secondary clone contain the majority of mutations present in the founder clone but have acquired
a distinct set of new mutations not shared with the founder.
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in our never-smoker sample. A variety of genes have been re-
ported to be 50 partners in ROS1 fusions, and it is not known
whether the 50 partner plays a role in the oncogenic activity of
the fusion kinase (Rikova et al., 2007; Takeuchi et al., 2012).
Apart from fusion kinases, an in-frame fusion was detected
between the RASSF1A (RAS association domain family protein
1) and TTYH2 (Tweety, Drosophila homolog of 2) genes. Another
novel fusion consisted of a transcription factor in the 30 end:
FZR1-NFIC. NFIC (nuclear factor I/C) is a dimeric DNA-binding
protein and functions as a cellular transcription factor. FZR1, in
association with the APC gene, is involved in the regulation of
mitosis and meiosis.
Integrated Analyses of the Whole-Genome
and Transcriptome Data
One of the major strengths of our study is the integration of
whole-genome and transcriptome sequencing. Starting with
3,726 tier 1 variants (point mutations only) from all samples
identified by WGS, we characterized the expression of each
gene by digital (NGS-based) RNA-seq (Extended Experimental
Procedures). The median read coverage from RNA-seq for all
tier 1 variant positions was 243, but in expressed genes, the
median read coverage reached 1293. We observed significant
concordance in variant identification between genome and
transcriptome sequencing. Transcriptome sequencing con-
firmed the presence of 40% of the variants identified by WGS
(at least one RNA-seq read) despite the observation that 34%
of variants identified in WGS data were from a nonexpressed
allele, and 3% of variants from highly expressed genes were
not sufficiently covered at the variant positions. We utilized
the RNA-seq data to further classify variants into four categories
according to their expression patterns: expressed, mutant
biased, wild-type biased, and silent gene (Figures 3A and 3B,
Table S18, and Extended Experimental Procedures). The
genomes of lung cancer from never-smokers had a higher
proportion of expressed variants (49.4%) than tobacco smokers
(29.1% or 27.0% if the hypermutated LUC9 is excluded). The
number of expressed variants that are biased toward the
mutant allele is a small proportion of all variants (9.6%) (Fig-
ure 3B). For these variants, the mutant allele had a significantly
higher variant allele frequency (>20% higher) in the RNA
compared to the DNA. Notably, a few genes (KRAS, TP53,
GTF3C1, PLEKHA6, and SGOL2) showed mutant-biased over-
expression relative to the wild-type allele in more than one
sample. For example, KRAS mutations were detected in five
of the 17 samples, and in all of these, the mutant allele was pref-
erentially expressed (Table S19). We did not identify copy
number amplification in the mutant-biased expression of the
KRAS gene. KRAS and TP53 were highly expressed (above
the 75th percentile) in all 17 cases, and eight of nine KRAS/
TP53 mutations occurred in smokers. KRAS and TP53 muta-(C) Tumor clonality plot of a monoclonal tumor from a never-smoker (LUC11).
(D) Tumor clonality plot of a biclonal tumor from a never-smoker (LUC15) with an
(E) Tumor clonality plot from a tobacco smoker (LUC9) with two distinct clones
the sub clone has a mean tumor variant allele frequency of 20.4%.
(F) Tumor clonality plot of a biclonal tumor from a tobacco smoker (LUC10) with
See also Figure S1, Data S3, and Tables S11, S14, and S15.
Ctions were mutually exclusive in our 17 cases (Figure 3C),
although previous studies showed that they could be present
in the same samples (Ding et al., 2008). Although the VAFs
observed in WGS and RNA-seq are generally correlated (Fig-
ure 3D), rare cases such as KRAS and TP53 deviate from the
expected VAF considerably. The mechanism underlying the
observed difference in VAFs at the DNA and RNA level for these
genes remains unknown.
Interestingly, we observed a lower mutation frequency in tier 1
than in tiers 2 and 3 for all 17 cases, and the average ratios of
tier 1 versus tier 2 and 3 frequencies are 0.628 and 0.700 for
never-smokers and smokers, respectively (Figures 4A and 4B)
(the former light smoker, LUC1, was not included in the
calculation and neither was the tier 3 mutation rate for the hyper-
mutated sample, LUC9). This observation is statistically signifi-
cant (p = 1.526 3 105), suggesting that selection pressure
and transcription-coupled repair for coding mutations might be
responsible for the reduced mutation rate in tier 1. Our result is
consistent with the genome-wide analyses of mutation frequen-
cies in a melanoma cell line (Pleasance et al., 2010a) and a lung
cancer cell line from a smoker (Pleasance et al., 2010b). Further,
we investigated the relationship between mutation frequency
and gene expression level and found that highly expressed
genes (FPKM >15) have less than four mutations per Mbp,
whereas genes that are not expressed (FPKM = 0) have close
to 14 mutations per Mbp. Thus, our analysis revealed a negative
correlation between gene expression level and mutation
frequency in lung cancers (correlation coefficient = 0.49, p =
0.1804), which is consistent with transcription-coupled repair
mechanism (Figure 4C).
Somatically Altered Pathways
PathScan (Wendl et al., 2011) analysis was performed to identify
significant clusters of point mutations involving genes in
annotated KEGG (Kyoto Encyclopedia of Genes and Genomes)
pathways. The analysis identified 50 pathways with statistically
significant (p < 0.05) enrichment of mutations (Table S20 and
Extended Experimental Procedures). We subsequently incorpo-
rated information regarding indels, copy number variations, and
messenger RNA (mRNA) expression level changes involving
individual genes in the significant pathways. Based on this anal-
ysis, we identified several pathways that are affected in lung
cancer, including JAK/STAT pathway (Figure 5A).
Genes involved in extracellular matrix (ECM) interaction, focal
or cell adhesion, and cell-cycle pathways were significantly
enriched in lung cancer. ECM interaction and cell adhesion
genes play important roles in morphogenesis, maintenance of
cellular and tissue structure, cell migration, and proliferation.
Similarly, there was significant enrichment of genes involved
in cell cycle, including the PRKDC gene that was recurrently
mutated in three patient samples. In addition, there wereEGFR mutation in the founder clone.
. The founder clone has a mean tumor variant allele frequency of 41.1%, and
a KRAS mutation in the founder clone.
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   Categories of variant expression in RNA-seq
    Observed variant expression     Mutation status and expression level
     WGS and RNA-seq variant allele frequencies      KRAS & TP53 mutation positions
KRAS
Smokers Non-Smokers
n = 10 17
9
13
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Figure 3. Mutant Biased Expression of KRAS and TP53 Somatic Variants
(A) A line diagramdepicting variant expression categories for heterozygousmutations from a diploid genome. Amaternal (a) and paternal (b) allele of chromosome
3 is depicted with four example genes enlarged. Each gene contains a heterozygousmutation on the b allele, depicted as a red line. Each gene example illustrates
a distinct variant expression pattern by displaying differing numbers of transcripts from each allele being generated from each locus. The FPKM is represented
as differing numbers of transcripts generated from each locus, and the VAF is calculated as the proportion of these transcripts deriving from the mutant allele
and containing the variant base.
(B) The proportion of variants corresponding to each of the four variant expression categories is summarized for all 17 lung cancers (‘‘other’’ refers to cases in
which the classification was ambiguous due to marginal sequencing coverage). The total number of variants (n) is provided for each patient, and the cases are
grouped by smoker status.
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mutations involving the cyclins CCNA1 and CCNB3 that are
essential for activation of cyclin-dependent kinases (CDKs) and
progression of cell cycle. We also identified significant enrich-
ment of mutations in the JAK-STAT (p = 0.04) pathway in our
sample set. Janus kinases are a family of tyrosine kinases that
are involved in cytokine receptor signaling, and JAK2 in partic-
ular mediates signaling for class II cytokine receptors, cytokine
receptors that utilize the gc receptor subunit, and receptors
that utilize the gp130 subunit (Rodig et al., 1998). The gain-of-
function V617F mutation in the pseudokinase domain of the
JAK2 gene leads to constitutive activation of the kinase domain
and is associated with uncontrolled hematopoietic cell prolifera-
tion in various myeloproliferative neoplasms (Kralovics et al.,
2005). However, it is not known whether mutations involving
JAK2 play a significant role in solid epithelial tumors, particularly
in lung cancer. Recently, JAK2 (V617F) mutations were reported
in a small proportion (1%) of patients with lung cancer (Lipson
et al., 2012). In our sample set, we identified two patients with
missense mutations (M532V and V615L) in the protein kinase 1
domain of the JAK2 gene. The detection of recurrent mutations
in the protein kinase domain of the JAK2 gene, as well as
mutations in other genes involved in the JAK-STAT pathway
(JAK3 and STAT1), indicate that activation of this pathway may
be oncogenic in a subset of patients with lung cancer (Figures
5A and 5B). These findings assume further importance with
the development of drugs that effectively target activating muta-
tions in the JAK2 gene. In addition, we identified that several
other pathways were significantly affected in lung cancer,
including G-protein-coupled receptor, ion channels, chemokine
signaling, calcium signaling pathways, immune modulation, and
ErbB signaling.Therapeutic Targets
The use of whole cancer genome sequencing and/or tran-
scriptome sequencing to identify therapeutic targets has been
recently reported (Jones et al., 2010b). Apart from previously
characterized activating mutations in the tyrosine kinase domain
of the EGFR gene, we identified potential therapeutic targets,
including point mutations in the HGF, MET, JAK2, and EPHA3
genes and fusions including KDELR2-ROS1 and EML4-ALK. In
an effort to comprehensively identify therapeutic targets in lung
cancer, we matched gene alterations, including point mutations,
copy number amplifications, and high gene expression levels
with novel compounds that are currently being evaluated for
the treatment of lung cancer (Somaiah and Simon, 2011) (Fig-
ure 6). As a result, we identified 54 genes with potentially
druggable alterations in our 17 lung cancer patients with several
novel therapeutic targets, including tyrosine kinases (JAK,(C) Box plots are used to display the expression of FPKM expression values fo
are displayed by colored triangles and circles, respectively, and patients with a m
(D) The correlation between VAF calculated from WGS and RNA-seq read counts
the gene harboring each variant is indicated by a yellow-to-red color scale where
KRAS is highlighted as an example of a variant with a VAF that is higher in the R
(E) The amino acid position of each KRAS and TP53mutation is depicted relative
domains.
See also Tables S7, S17, S18, and S19.
CBRAF, PIK3CG, IGF1R, MET, RET, and FGFR1), heat shock
protein (HSP90AA1), and histone deacetylases (HDAC1,
HDAC2, HDAC6, and HDAC9). A median of 11 (range 7–17)
potentially druggable targets was found for each patient. Novel
and recurrent druggable point mutations included PRKCB2,
MET, JAK2, HGF, and ERBB4, in addition to previously well-
known targets such as KRAS, EGFR, and BRAF. These findings
clearly illustrate that there are several novel potential thera-
peutic targets in patients with lung cancer that require further
exploration.DISCUSSION
Lung cancer is a molecularly heterogeneous disease. The tumor
genomic landscape is markedly distinct in never-smokers
compared to smokers in several respects: 1) significantly higher
mutation frequencies observed in smokers; 2) different mutation
spectrum between smokers (C:G/A:T predominant) and never-
smokers (C:G/T:A predominant); and 3) distinctive sets of
mutations identified in never-smokers (EGFR mutations and
ROS1 and ALK fusions) and smokers (KRAS, TP53, BRAF,
JAK2, and JAK3 and mismatch repair gene mutations). Apart
from point mutations, we identified a significant number of
structural variations and fusion genes. Going forward, com-
prehensive genomic analyses of whole genomes and tran-
scriptomes of a large number of lung cancer samples from
lifelong never-smokers will be needed to better understand
molecular genetics and to guide therapy in this unique subset
of patients.
Aberrations in DNA repair pathway, chromatin modifica-
tion genes, and novel fusions involving metabolic pathways
identified in our study present novel therapeutic opportunities.
It is possible that these previously poorly characterized molec-
ular lesions in lung cancer may represent the proverbial Achilles’
heel for targeted treatment. For example, certain DNA repair
pathway lesions may confer unusual susceptibility of cancer
cells to PARP inhibitors, much like those seen in BRCA-deficient
cancer types. The role of epigenetic therapy in general—and
histone deacetylase (HDAC) inhibitors in particular—should be
studied in lung cancer, given the number of events in chromatin
modifier genes we identified in this study.
Deep digital sequencing provides a large number of events
that can be used to precisely estimate clonal size and mutational
evolution over time during the natural course of disease pro-
gression and in response to selection pressure exerted by
therapy. It is unlikely that current therapies would produce
lasting remission or cure in advanced lung cancer unless
dominant genetic alterations in the founder clone and emergingr all detected genes in all 17 cases. The expression level of KRAS and TP53
utation in these genes are indicated in red.
is depicted as a scatterplot for a single patient. The FPKM expression level of
yellow indicates low gene expression and red indicates high gene expression.
NA than in the WGS data for this patient.
to the open reading frame of the gene, along with the position of known protein
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Figure 4. Analysis of Transcription-Coupled Repair across the
Genome
(A and B) (A) The mutation rate is assessed independently in each of tiers 1–3
for never-smokers and (B) smokers. Smokers LUC1 and LUC9 are omitted
from (B) due to their extremely low and extremely high mutation rates,
respectively. Both (A) and (B) clearly show that the coding space in these tumor
genomes incurs fewer mutations than other regions in the genomes.
(C) Genes were binned based on the FPKM values derived from RNA
expression analysis of the tumor samples, and then the mutation rate
(validated somatic mutations per adequately covered Mbp) was calculated
for each expression level bin. The graph shows that the lowest mutation rates
occur in the most highly expressed genes.
See also Data S2 and Tables S7, S8, and S9.secondary clones are targeted specifically for therapy. A sys-
tematic approach to collect tissue samples—not only at the
time of diagnosis but serially at the times of relapse to chronicle
the dynamic clonal evolution that occurs over time and possibly
at different metastatic sites—is absolutely critical to make major
advances in therapy.1130 Cell 150, 1121–1134, September 14, 2012 ª2012 Elsevier Inc.Only through a comprehensive assessment of WGS and
transcriptomes in large numbers of carefully curated and well-
annotated samples will we able to catalog potentially significant
point mutations and structural variations that led to critical
perturbations in the cellular homeostasis. Moreover, the cancer
research community should radically overhaul the current
approach to drug development and initiate a series of steps
to study comprehensively genomic evolution over time in well-
defined cohorts of patients enrolled in clinical trials. Comprehen-
sive genomic characterization efforts to catalog somatically
altered pathways will improve our understanding of the molec-
ular genetics of lung cancer and will identify novel therapeutic
targets. Functional studies in the laboratory and thoughtfully
designed clinical studies will be needed to fully harness the
data from genomic studies such as ours.
EXPERIMENTAL PROCEDURES
Pointmutations and indels identified byWGSof 17 tumor-normal
pairs were classified into four tiers as described previously
(Mardis et al., 2009). Custom sequence capture arrays from
Roche Nimblegen were used to validate all putative WGS
mutations. Variants of interest identified by WGS were extended
by recurrence screening in an independent set of 96 primary
lung adenocarcinomas. RNA-seq data were generated for all
17 tumors and for a single, matched normal adjacent tissue
with 11,578–14,507 genes detected as expressed in each tumor.
RNA-seq analysis involved alignment using TopHat (Trapnell
et al., 2012) and assembly and expression estimation by
Cufflinks (Trapnell et al., 2012) using a known set of reference
transcripts from Ensembl v.58. The expression status of single-
nucleotide variants was assessed by examination of TopHat
alignment and Cufflinks transcript expression estimates, allow-
ing the classification of each putative variant from WGS
into one of five expression patterns (Extended Experimental
Procedures).
Expressed gene fusions were identified by combining the
results of ChimeraScan (Iyer et al., 2011), defuse (McPherson
et al., 2011), and BreakFusion (Chen et al., 2012). Downstream
analyses included the cross-validation of fusion events detected
in RNA data withWGSSV predictions, tumor clonality estimates,
and several analyses that are part of the MuSiC analysis suite
(Dees et al., 2012). Tumor clonality estimation includes the
identification of peaks in the kernel density estimates of deep-
read count variant allele frequencies at somatic SNV sites in
copy-number-neutral genomic regions from the tumor genomes.
MuSiC analyses included the identification of significantly
mutated genes under the statistical consideration of seven
separate mutational mechanism categories, a proximity analysis
used to identify recurrently mutated functional domains, and
a comparison of the SNVs discovered in this data set with those
in the COSMIC database. Global pathway analysis was per-
formed by using PathScan (Wendl et al., 2011), followed by
a more focused analysis of the KEGG cancer pathways (Kane-
hisa and Goto, 2000; Kanehisa et al., 2012) and the JAK-STAT
pathway in particular.
To identify putative druggable targets, a candidate gene list
was generated by identifying genes with nonsilent mutations,
AB
Figure 5. Alterations in JAK/STAT Pathway and Integration of Somatic Alterations and High RNA Expression in Significant KEGG Pathways
(A) Heatmap of significantly overrepresented gene pathways in lung cancer (p < 0.05). The number of gene members of each KEGG cancer pathway (‘‘KEGG
pathways in cancer’’ or ‘‘hsa05200’’) altered by one of four alteration types in at least one patient is summarized as a heatmap. The KEGG pathway name is listed
on the y axis at the left, and the total number of genes comprising that pathway is provided (labeled as n). The number within each box represents the number
of genes altered in at least one patient for each alteration type. The percentage of all gene members of the KEGG pathway altered in at least one patient by at
least one alteration type is provided on the right side. The heatmap is sorted by this percentage.
(B) Molecular alterations in JAK-STAT pathway in patients with non-small cell lung cancer. Genes that were found to be altered in the 17 lung cancer samples are
labeled with the type of molecular change (E, overexpression; C, copy number alteration; M, mutation; and S, structural variation) and the frequency.
See also Data S3 and Tables S3, S9, S11, S18, and S20.
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Figure 6. Potential Therapeutic Targets in Non-Small Cell Lung Cancer
Graphical representation of the various therapeutic targets in each patient sample. Patients are listed on the x axis. Target genes identified as altered in one or
more patients and the drugs that targeted these genes are listed on the y axis (gene symbols on the left side and corresponding drug names on the right side).
Where display of all drug names was not practical, the list was abbreviated. The numbers in parentheses indicate the total number of drugs currently available for
each gene target. A box representing each gene-drug combination for each patient is colored according to the class of gene alteration: red for SNVs, orange for
indels, purple for CNV amplifications, and green for RNA overexpression (Extended Experimental Procedures). Gene targets are grouped and labeled on the left
side of the plot according to the therapeutic class of their targeted agents. See also Tables S3, S4, S9, S11, S15, S16, and S17.copy number amplifications, and/or high RNA expression.
The resulting gene list was intersected with a list of ‘‘known’’
drug-gene interactions currently used or under investigation
in lung cancer. The same candidate gene list was also annotated
against lists of genes that are thought to be potential
targets for novel drug development according to a previously
described approach (Hopkins and Groom, 2002; Russ and
Lampel, 2005).
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